Asthma

>

Latest News

Tezepelumab for COPD Moves into Phase 3 Planning, Says Amgen / image credit Amgen logo ©MichaelVi/stock.adobe.com
Tezepelumab for COPD Moves into Phase 3 Planning

April 17th 2024

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children Aged 6-11 Years with Severe Asthma / Image credit: ©Argus/AdobeStock
FDA Approves Benralizumab as Add-On Maintenance Therapy for Children Aged 6-11 Years with Severe Asthma

April 11th 2024

Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month  / image credit inhalers ©beltado/stock.adobe.com
Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month

March 7th 2024

Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improves Lung Function, Asthma Control: Daily Dose / image credit: ©New Africa/AdobeStock
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improves Lung Function, Asthma Control: Daily Dose

February 29th 2024

Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma / Image credit: ©molekuule.be/AdobeStock
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma

February 23rd 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.